YES!!! It is here. Phase II vaccine trial for Her2 3+

['lizbeth]

Eligible breast cancer patients will be randomized to receive NeuVax + GM-CSF (granulocyte macrophage-colony stimulating factor) + trastuzumab or trastuzumab + GM-CSF alone in the adjuvant setting following surgery. The primary endpoint of the study is invasive disease-free survival and enrollment is expected to complete in the second half of 2016, followed by a 3-year follow-up period. There are three categories of high-risk patients that qualify for the trial:

Patients who received neoadjuvant therapy (before surgery) with an approved regimen that includes trastuzumab and at least four cycles (12 weeks) of taxane-containing chemotherapy but fail to obtain a pathological complete response (pCR) at surgery, regardless of hormone receptor status.
Patients who undergo surgery as a first intervention and are found to be pathologically node-positive with at least four positive lymph nodes, regardless of hormone receptor status.
Hormone receptor negative breast cancer patients who undergo surgery as a first intervention and are found to have one, two or three positive lymph nodes.

Jaykay, The vaccine is for those who are "NED" cancer free after initial treatment, but fall into 3 high risk categories.

Waterdreamer, that is better, funny. I will call you an "Impatient" because you are tired of dealing with cancer. I am HLA A2 positive, so am quite happy about Neuvax

[thinkpositive]

Jaykay, I'm with you. I wish I could join this vaccine trial. Because I had pathological complete response after responding to neoadjuvant treatment, I don't qualify.